Bicycle Therapeutics Advances EphA2 Oncology Pipeline With New Data

Bicycle Therapeutics ( (BCYC) ) has shared an update.

On April 20, 2026, Bicycle Therapeutics reported new clinical and preclinical data from its EphA2 pipeline at the AACR Annual Meeting, highlighting progress for its Bicycle Drug Conjugate nuzefatide pevedotin in hard-to-treat tumors. Phase 1/2 combination results in previously treated metastatic urothelial cancer showed a 40% confirmed response rate in EphA2-positive patients and a favorable tolerability profile when nuzefatide was combined with nivolumab.

Based on dose-ranging work, the company selected 8mg/m² every two weeks as the preferred monotherapy dose and, after opening enrollment in March 2026, dosed the first patient in its Phase 2 trial for second-line and later pancreatic ductal adenocarcinoma in April 2026. Additional human imaging and xenograft data in pancreatic and head and neck cancers underscored EphA2’s promise as a novel oncology target and strengthened Bicycle’s bid to differentiate itself in targeted therapies and radiopharmaceuticals, potentially expanding treatment options in indications with limited effective therapies today.

The most recent analyst rating on (BCYC) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Bicycle Therapeutics stock, see the BCYC Stock Forecast page.

Spark’s Take on BCYC Stock

According to Spark, TipRanks’ AI Analyst, BCYC is a Neutral.

The score is primarily held back by weak financial quality—large ongoing losses and an accelerating cash burn—despite strong revenue growth and a relatively low-debt balance sheet. Technicals also reflect a sustained downtrend and weak momentum. A positive corporate update and stated runway into 2028 provide some support, but do not fully offset the funding and profitability risks implied by current cash outflows.

To see Spark’s full report on BCYC stock, click here.

More about Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of fully synthetic bicyclic peptide medicines, known as Bicycle molecules, for diseases underserved by existing therapies. Its pipeline includes Bicycle Drug Conjugates such as nuzefatide pevedotin targeting EphA2 and zelenectide pevedotin targeting Nectin-4, radioconjugates for radiopharmaceutical use, and immune cell agonists, with operations centered in Cambridge, UK, and Lexington, Mass.

The company leverages its proprietary constrained peptide technology to achieve high-affinity, selective binding to historically challenging targets, positioning it as an innovator in oncology and other therapeutic areas. Through internal programs and partnerships, Bicycle Therapeutics is exploring applications of its platform across multiple cancer types and additional disease indications.

Average Trading Volume: 455,930

Technical Sentiment Signal: Sell

Current Market Cap: $366.3M

For an in-depth examination of BCYC stock, go to TipRanks’ Overview page.